Safety and efficacy of CYT387, a JAK-1/2 inhibitor, for the treatment of myelofibrosis

被引：0
|
作者：
Pardanani, A. D.
Caramazza, D.
George, G.
Lasho, T. L.
Hogan, W. J.
Litzow, M. R.
Begna, K.
Hanson, C. A.
McClure, R. F.
Bavisotto, L. M.
Smith, G.
Kowalski, M.
Sirhan, S.
Roberts, A. W.
Gupta, V.
Gotlib, J.
Tefferi, A.
机构：
[1] Mayo Clin, Rochester, MN USA
[2] Porta Clin PLLC, Seattle, WA USA
[3] YM BioSci, Mississauga, ON, Canada
[4] McGill Univ, Ctr Hlth, Montreal, PQ, Canada
[5] Royal Melbourne Hopsital, Parkville, Vic, Australia
[6] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[7] Stanford Univ, Sch Med, Stanford, CA 94305 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6514
引用
收藏
页数：1
相关论文
共 50 条
  • [41] CYT387, a Novel JAK2 Inhibitor, Suppresses IL-13-Induced Epidermal Barrier Dysfunction Via miR-143 Targeting IL-13Rα1 and STAT3
    Yan Zu
    Xiao-Fei Chen
    Qiang Li
    Shu-Ting Zhang
    Biochemical Genetics, 2021, 59 : 531 - 546
  • [42] Novel JAK-1 inhibitor upadacitinib as a possible treatment for refractory SAPHO syndrome: A case report
    Ma, Mingwei
    Lu, Siyi
    Hou, Xiujuan
    Li, Chen
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2023, 26 (11) : 2335 - 2337
  • [43] Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis
    Ostojic, Alen
    Vrhovac, Radovan
    Verstovsek, Srdan
    FUTURE ONCOLOGY, 2011, 7 (09) : 1035 - 1043
  • [44] Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
    Genovese, Mark C.
    Smolen, Josef S.
    Weinblatt, Michael E.
    Burmester, Gerd R.
    Meerwein, Sebastian
    Camp, Heidi S.
    Wang, Li
    Othman, Ahmed A.
    Khan, Nasser
    Pangan, Aileen L.
    Jungerwirth, Steven
    ARTHRITIS & RHEUMATOLOGY, 2016, 68 (12) : 2857 - 2866
  • [45] Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK-1 Inhibitor, After Short-Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials
    Vanhoutte, Frederic
    Mazur, Minodora
    Voloshyn, Oleksandr
    Stanislavchuk, Mykola
    Van der Aa, Annegret
    Namour, Florence
    Galien, Rene
    Meuleners, Luc
    van 't Klooster, Gerben
    ARTHRITIS & RHEUMATOLOGY, 2017, 69 (10) : 1949 - 1959
  • [46] Significant Improvement In Quality Of Life (QoL) In Patients With Chronic Myeloproliferative Neoplasms and Myelofibrosis Treated With JAK-1 and JAK-2 Inhibitor Ruxolitinib. A Single Institution Experience In Mexico
    Vargas-Viveros, Pablo
    Monroy, Rafael Hurtado
    Candelaria-Hernandez, Myrna
    BLOOD, 2013, 122 (21)
  • [47] Assessing efficacy in myelofibrosis treatment: a focus on JAK inhibition
    Komrokji, Rami
    Verstovsek, Srdan
    EXPERT REVIEW OF HEMATOLOGY, 2012, 5 (06) : 631 - 641
  • [48] CYT387 Inhibits the Hyperproliferative Potential of Fibroblast-like Synoviocytes via Modulation of IL-6/JAK1/STAT3 Signaling in Rheumatoid Arthritis
    Srivastava, Susmita
    Samarpita, Snigdha
    Ganesan, Ramamoorthi
    Rasool, Mahaboobkhan
    IMMUNOLOGICAL INVESTIGATIONS, 2022, 51 (06) : 1582 - 1597
  • [49] Energy expenditure in myelofibrosis patients treated with a JAK1/2 inhibitor
    Tremblay, Douglas
    Dougherty, Mikaela
    Mascarenhas, John
    Gallagher, Emily Jane
    FRONTIERS IN ENDOCRINOLOGY, 2023, 14
  • [50] Effect Of The JAK1/2 Inhibitor GS-o387 (momelotinib) On The Anemia Associated With a Preclinical Murine Model Of Human Primary Myelofibrosis
    Villeval, Jean-Luc
    Moratal, Claudine
    Debeurme, Franck
    Lacout, Catherine
    Solary, Eric
    Vainchenker, William
    Burns, Christopher J.
    Smith, Gregg
    BLOOD, 2013, 122 (21)
12345